Recent Finacing
Recent Raise
Advaxis develops immunotherapies that reprogram HPV E7–expressing cells to elicit cellular immune responses, pursuing multiple Phase 2 trials for cervical and head‑and‑neck cancers and a preclinical prostate program.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor